1. Home
  2. PFL vs ITOS Comparison

PFL vs ITOS Comparison

Compare PFL & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFL
  • ITOS
  • Stock Information
  • Founded
  • PFL 2003
  • ITOS 2011
  • Country
  • PFL United States
  • ITOS United States
  • Employees
  • PFL N/A
  • ITOS N/A
  • Industry
  • PFL Finance Companies
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PFL Finance
  • ITOS Health Care
  • Exchange
  • PFL Nasdaq
  • ITOS Nasdaq
  • Market Cap
  • PFL 332.7M
  • ITOS 342.6M
  • IPO Year
  • PFL N/A
  • ITOS 2020
  • Fundamental
  • Price
  • PFL $8.30
  • ITOS $8.23
  • Analyst Decision
  • PFL
  • ITOS Strong Buy
  • Analyst Count
  • PFL 0
  • ITOS 3
  • Target Price
  • PFL N/A
  • ITOS $33.67
  • AVG Volume (30 Days)
  • PFL 113.7K
  • ITOS 612.3K
  • Earning Date
  • PFL 01-01-0001
  • ITOS 11-12-2024
  • Dividend Yield
  • PFL 11.53%
  • ITOS N/A
  • EPS Growth
  • PFL N/A
  • ITOS N/A
  • EPS
  • PFL N/A
  • ITOS N/A
  • Revenue
  • PFL N/A
  • ITOS $35,000,000.00
  • Revenue This Year
  • PFL N/A
  • ITOS $271.18
  • Revenue Next Year
  • PFL N/A
  • ITOS N/A
  • P/E Ratio
  • PFL N/A
  • ITOS N/A
  • Revenue Growth
  • PFL N/A
  • ITOS N/A
  • 52 Week Low
  • PFL $6.98
  • ITOS $7.99
  • 52 Week High
  • PFL $8.62
  • ITOS $18.75
  • Technical
  • Relative Strength Index (RSI)
  • PFL 30.61
  • ITOS 32.69
  • Support Level
  • PFL $8.16
  • ITOS $8.92
  • Resistance Level
  • PFL $8.60
  • ITOS $9.71
  • Average True Range (ATR)
  • PFL 0.08
  • ITOS 0.55
  • MACD
  • PFL -0.03
  • ITOS 0.06
  • Stochastic Oscillator
  • PFL 31.82
  • ITOS 13.95

About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest

PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Share on Social Networks: